BioCryst Pharmaceuticals (BCRX) Plunges 5.32% Amid Patent Lawsuit

BioCryst Pharmaceuticals (BCRX) shares plummeted 5.32% today, hitting their lowest level since June 2024, with an intraday decline of 11.08%.

BioCryst Pharmaceuticals Inc. has filed a patent infringement lawsuit to safeguard its drug ORLADEYO from generic competition. This legal action could potentially impact the company's market position and financial performance, influencing investor sentiment and stock valuation. The lawsuit aims to protect the company's intellectual property and maintain its competitive edge in the market. The outcome of this legal battle will be closely watched by investors, as it could significantly affect the company's future prospects and stock performance.